1Wills RJ.Clinical pharmacokinetics of interferons[J].Clin Pharmacokinet,1990,19:390-399.
2Kozlowski A,Charles SA,Harris JM.Development of pegylated interferons for the treatment of chronic hepatitis C[J].Biodrugs,2001,15:419-429.
3Modi MW,Fulton JS,Wright TL,et al.Clearance of pegylated (40kDa) interferon α-2a (Pegasys) is primarily hepatitis[J].Hepatology,2000,32:371A.
4Kamal SM,Fehr J,Roesler B,et al.Peginterferon alone or with ribavirin enhances HCV-specific CD4T-helper 1 responses in patients with chronic hepatitis C[J].Gastroenterology,2002,123 (4):1070-1083.
5Algranati NE,Sy S,Modi M.A branched methooxy40 kDa polyethylnen glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α -2a(PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC)[J].Hepatology,1999,40:190.
6Xu Z-X,Hoffman J,Patel Ⅰ,et al.Singledose safety/tolerability and pharmacokinetics /pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon(PEG-IFN) and interferon alpa-2a (IFN α-2a) to heathy subjects[J].Hepatology,1998,28:702A.
